Navigation Links
Genta Granted Extension to Achieve Compliance with NASDAQ Listing Requirements
Date:3/27/2008

BERKELEY HEIGHTS, N.J., March 27 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA) announced that the NASDAQ Listing Qualifications Panel has granted the Company's request for an extension of time to achieve full compliance with the applicable NASDAQ listing requirements. Pursuant to the Panel's decision, the listing of the Company's common stock will be transferred from The NASDAQ Global Market to The NASDAQ Capital Market, effective with the open of trading on Friday, March 28, 2008. The Company will continue to trade under its existing symbol, GNTA.

As disclosed on November 16, 2007 and January 11, 2008, the Company was previously notified by NASDAQ that it no longer satisfied the stockholders' equity requirement for continued listing on The NASDAQ Global Market, as set forth in Marketplace Rule 4350(a)(3). In response, the Company appeared before the Panel at a hearing on February 21, 2008.

The Company's continued listing on The NASDAQ Capital Market is subject to the Company's compliance with certain conditions, including evidence of the Company's ability to sustain compliance with the $2.5 million stockholders' equity requirement, as set forth in Marketplace Rule 4310(c)(3), and the submission of the required transfer application to NASDAQ within the next seven days. The Company currently expects to be able to comply with the Panel's conditions for continued listing on The NASDAQ Capital Market; however, there can be no assurance that the Company will be able to achieve or sustain such compliance.

About Genta

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Auditors for Genta Incorporated Express Going Concern Qualification
2. Genta Announces Senior Management Changes
3. Genta Announces Common Stock Offering of Approximately $3.1 Million
4. Genta Incorporated to Present at the BIO CEO & Investor Conference
5. Genta Receives Notice of Non-Compliance With NASDAQ Rule
6. Genta Receives NASDAQ Non-Compliance Notice
7. Genta Incorporated to Present at Lazard Capital Markets 4th Annual Healthcare Conference
8. Syngenta and The Royal Society of Chemistry Launch African Science Initiative
9. Genta Receives Notice of Non-Compliance with Listing Requirement for NASDAQ Global Market
10. Genta Completes Appeal of FDA Decision for Genasense(R) in CLL
11. Syngenta Licenses Chromatin Gene Stacking Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015   Cypher Genomics, Inc., the ... SQNM ), the leading molecular diagnostics ... generation noninvasive prenatal tests (NIPT). Through this agreement, ... Mantis™, to advance analysis of clinically-relevant fetal sub-chromosomal ...
(Date:12/24/2014)... , Dec. 24, 2014  United Therapeutics Corporation (NASDAQ: ... (NYSE: MDT ) has submitted a pre-market ... (FDA) for the use of Medtronic,s SynchroMed ® ... catheter) for use with United Therapeutics, Remodulin ® ...
(Date:12/24/2014)... Missouri (PRWEB) December 23, 2014 GMO corn ... company, Syngenta, are in the process of being consolidated in ... is In Re: Syngenta AG MIR 162 Corn Litigation, MDL ... of Kansas. , Management of the Syngenta GMO corn multidistrict ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 The ... as its definition, classification, application and industry overview. ... and product cost structure. Production is separated by ... upstream raw materials, equipment, downstream client survey, marketing ...
Breaking Biology Technology:Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
... of Wisconsin-Madison spinout that has sped to the finals in ... stop to the annual flu vaccine hoopla, among other things. ... are developing two drugs based on antiviral peptides discovered in ... while the other targets some sexually transmitted viruses such as ...
... recent decision to pull Pfizer Cox-2 inhibitor Bextra from the marketplace ... up in the Merck Vioxx dilemma months ago and its stock ... $25 per share in February. It has recently moved up to ... about 30 percent in the last 12 months. , ,Though Pfizer ...
... Sensient Technologies Corp. (NYSE:SXT) reported $12.8 million ... quarter ended March 31. Diluted earnings per share were 27 ... flavors and fragrances. , ,Revenue was down $3 million since ... a reduction of $19.2 million. , ,Results for the first ...
Cached Biology Technology:UW-Madison spinoff Pedrus finds more to business planning than good science 2UW-Madison spinoff Pedrus finds more to business planning than good science 3Why are new drugs failing? 2Why are new drugs failing? 3Why are new drugs failing? 4Why are new drugs failing? 5Why are new drugs failing? 6
(Date:12/17/2014)... 2014  Automation is fundamentally transforming the travel experience and ... Over the past decade, ePassports, biometric readers, and secure ... through border control via eGates and Automated Passport Control ... and land borders across the globe. ...
(Date:12/11/2014)... Research and Markets , ... announced the addition of the "Biometrics Market in ... One major trend emerging in this market ... it is important to upgrade biometric solutions to the ...
(Date:12/11/2014)... WINSTON SALEM, N.C. , Dec. 10, 2014  That blood ... for quite a while. Hypertension – the medical term for ... in the early 1800s, and the inflatable cuff that,s used ... That doesn,t, however, mean there,s nothing new about hypertension, its ...
Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... severed nerves could result in patients recovering in days or ... cellular mechanism similar to that used by many invertebrates to ... in the Journal of Neuroscience Research . "We ... minutes so that the behavior they control can be partially ...
... that make up half the biomass in the oceans ... over, mostly remain enigmatic. A few abundant groups have ... of the rest remain mysterious. Understanding how the ... is like trying to understand the solar system when ...
... fertile, excite our most basic urges, and as scientists have ... from women. But how? Now a team of scientists ... many genes influenced by the male and female sex hormones ... of male and female behaviors in mice. The UCSF ...
Cached Biology News:New procedure repairs severed nerves in minutes, restoring limb use in days or weeks 2Scientists coax shy microorganisms to stand out in a crowd 2Scientists coax shy microorganisms to stand out in a crowd 3Male and female behavior deconstructed 2Male and female behavior deconstructed 3Male and female behavior deconstructed 4